These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 39505850)

  • 1. The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia.
    Toscan CE; McCalmont H; Ashoorzadeh A; Lin X; Fu Z; Doculara L; Kosasih HJ; Cadiz R; Zhou A; Williams S; Evans K; Khalili F; Cai R; Yeats KL; Gifford AJ; Pickford R; Mayoh C; Xie J; Henderson MJ; Trahair TN; Patterson AV; Smaill JB; de Bock CE; Lock RB
    Blood Cancer J; 2024 Nov; 14(1):192. PubMed ID: 39505850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL.
    Evans K; Duan J; Pritchard T; Jones CD; McDermott L; Gu Z; Toscan CE; El-Zein N; Mayoh C; Erickson SW; Guo Y; Meng F; Jung D; Rathi KS; Roberts KG; Mullighan CG; Shia CS; Pearce T; Teicher BA; Smith MA; Lock RB
    Clin Cancer Res; 2019 Jul; 25(14):4493-4503. PubMed ID: 31015346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia.
    Moradi Manesh D; El-Hoss J; Evans K; Richmond J; Toscan CE; Bracken LS; Hedrick A; Sutton R; Marshall GM; Wilson WR; Kurmasheva RT; Billups C; Houghton PJ; Smith MA; Carol H; Lock RB
    Blood; 2015 Sep; 126(10):1193-202. PubMed ID: 26116659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An AKR1C3-specific prodrug with potent anti-tumor activities against T-ALL.
    Wang Y; Liu Y; Zhou C; Wang C; Zhang N; Cao D; Li Q; Wang Z
    Leuk Lymphoma; 2020 Jul; 61(7):1660-1668. PubMed ID: 32091283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells.
    Jamieson SM; Gu Y; Manesh DM; El-Hoss J; Jing D; Mackenzie KL; Guise CP; Foehrenbacher A; Pullen SM; Benito J; Smaill JB; Patterson AV; Mulaw MA; Konopleva M; Bohlander SK; Lock RB; Wilson WR
    Biochem Pharmacol; 2014 Mar; 88(1):36-45. PubMed ID: 24434189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent and Highly Selective Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors Act as Chemotherapeutic Potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
    Verma K; Zang T; Penning TM; Trippier PC
    J Med Chem; 2019 Apr; 62(7):3590-3616. PubMed ID: 30836001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.
    Mowday AM; Ashoorzadeh A; Williams EM; Copp JN; Silva S; Bull MR; Abbattista MR; Anderson RF; Flanagan JU; Guise CP; Ackerley DF; Smaill JB; Patterson AV
    Biochem Pharmacol; 2016 Sep; 116():176-87. PubMed ID: 27453434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
    Guise CP; Abbattista MR; Singleton RS; Holford SD; Connolly J; Dachs GU; Fox SB; Pollock R; Harvey J; Guilford P; Doñate F; Wilson WR; Patterson AV
    Cancer Res; 2010 Feb; 70(4):1573-84. PubMed ID: 20145130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AKR1C enzymes sustain therapy resistance in paediatric T-ALL.
    Bortolozzi R; Bresolin S; Rampazzo E; Paganin M; Maule F; Mariotto E; Boso D; Minuzzo S; Agnusdei V; Viola G; Te Kronnie G; Cazzaniga G; Basso G; Persano L
    Br J Cancer; 2018 Apr; 118(7):985-994. PubMed ID: 29515258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldo-Keto Reductase 1C3 Inhibitor Prodrug Improves Pharmacokinetic Profile and Demonstrates In Vivo Efficacy in a Prostate Cancer Xenograft Model.
    Maddeboina K; Jonnalagadda SK; Morsy A; Duan L; Chhonker YS; Murry DJ; Penning TM; Trippier PC
    J Med Chem; 2023 Jul; 66(14):9894-9915. PubMed ID: 37428858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coumarin-Based Aldo-Keto Reductase Family 1C (AKR1C) 2 and 3 Inhibitors.
    Jonnalagadda SK; Duan L; Dow LF; Boligala GP; Kosmacek E; McCoy K; Oberley-Deegan R; Chhonker YS; Murry DJ; Reynolds CP; Maurer BJ; Penning TM; Trippier PC
    ChemMedChem; 2024 Nov; 19(21):e202400081. PubMed ID: 38976686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach.
    Pippione AC; Giraudo A; Bonanni D; Carnovale IM; Marini E; Cena C; Costale A; Zonari D; Pors K; Sadiq M; Boschi D; Oliaro-Bosso S; Lolli ML
    Eur J Med Chem; 2017 Oct; 139():936-946. PubMed ID: 28881288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer.
    Liu C; Lou W; Zhu Y; Yang JC; Nadiminty N; Gaikwad NW; Evans CP; Gao AC
    Cancer Res; 2015 Apr; 75(7):1413-22. PubMed ID: 25649766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel AKR1C3 specific prodrug AST-3424 and its combination therapy in hepatocellular carcinoma.
    Xun C; Zhang Y; Zheng X; Qin S
    J Pharmacol Sci; 2023 Jun; 152(2):69-75. PubMed ID: 37169481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.
    Abbattista MR; Jamieson SM; Gu Y; Nickel JE; Pullen SM; Patterson AV; Wilson WR; Guise CP
    Cancer Biol Ther; 2015; 16(4):610-22. PubMed ID: 25869917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer.
    Liu C; Armstrong CM; Lou W; Lombard A; Evans CP; Gao AC
    Mol Cancer Ther; 2017 Jan; 16(1):35-44. PubMed ID: 27794047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AKR1C3 expression in T acute lymphoblastic leukemia/lymphoma for clinical use as a biomarker.
    Reddi D; Seaton BW; Woolston D; Aicher L; Monroe LD; Mao ZJ; Harrell JC; Radich JP; Advani A; Papadantonakis N; Yeung CCS
    Sci Rep; 2022 Apr; 12(1):5809. PubMed ID: 35388063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer.
    Hamid AR; Pfeiffer MJ; Verhaegh GW; Schaafsma E; Brandt A; Sweep FC; Sedelaar JP; Schalken JA
    Mol Med; 2013 Jan; 18(1):1449-55. PubMed ID: 23196782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulforaphane Preconditioning Sensitizes Human Colon Cancer Cells towards the Bioreductive Anticancer Prodrug PR-104A.
    Erzinger MM; Bovet C; Hecht KM; Senger S; Winiker P; Sobotzki N; Cristea S; Beerenwinkel N; Shay JW; Marra G; Wollscheid B; Sturla SJ
    PLoS One; 2016; 11(3):e0150219. PubMed ID: 26950072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships.
    Adeniji AO; Twenter BM; Byrns MC; Jin Y; Chen M; Winkler JD; Penning TM
    J Med Chem; 2012 Mar; 55(5):2311-23. PubMed ID: 22263837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.